Member Info for jmfw

Gmcc, thanks. Munroe's comments fit with my own view that Avacta could offer the tech for licensing to all those who want it. While, at the same time, developing new possibilities where they see opportunities.

I think that scenario would be very suitable for the sector.

Once the P1 data is released, think avacta will start to engage the media more. I have no doubt it'll be positive, maybe very.

"We believe this technology has the potential to markedly improve outcomes for cancer patients, particularly those with highly-resistant tumors.

“The pre|CISION® platform has been validated by compelling clinical data with faridoxorubicin (AVA6000, FAP-Dox), demonstrating a tumor-to-plasma payload concentration of 100:1 and a significant reduction in off-target toxicities despite dosing up to approximately 4x the dose of conventional doxorubicin. "

To me CC's tone has changed. This is not cautious but confident.

AI is behind the times.

Must be 26. Copied this heading from their webpage.

29 - 30 September 2026

Congress Centre Basel, Basel, Switzerland

Thanks Thompi. I'm not remotely versed in the technicalities of this science. However, it seems that presence of FAP in fibrosis, fibromyalgia etc has raised interest. The link below led me to consider the possibilities with our our platform (but only out of ignorance).

https://www.alliedacademies.org/articles/fap-and-fibrosis-advancements-in-understanding-tissue-remodeling.pdf

Thompi, according to the AI genie:

Condition - FAP Expression Level

Cancer - High

Wound Healing - Present

Embryonic Development - Present

Inflammation - Present

Normal Adult Tissues - Low

Inflammation could be interesting.

B2H. I came to the same conclusion on the 30th, & posted as much. I could very well be wrong, but thought

"there's also the opportunity for us to develop a partnership with another oncology drug in a potential partners pipeline.....I will commit to you that we will continue to update shareholders as soon as we are able to do so."

was illuminating.

Without factoring in:

"Delighted w/progress pre|CISION is making in clinic (more at #ESMO25) and excited to unveil a key development at AACR-NCI-EORTC in Boston in Oct" ??

Wyn, Yr 6.55. "The assumption is that healthcare will simply become ever more expensive but where is the income from the individual to pay for this?" etc.

Your reasoning implies that in future years there'll be little or no investment in health care. Is that what what you think? If so, why just that sector. Won't everything become more expensive? If so, the same question applies how will the individual pay (for anything)?

In this sense, the name Fari can be seen as an expression of wish for the person to have a prosperous and energetic life.

'A prosperous and energetic life.' Seems to fit with Avacta's moniker.

Forgetting the science, my take is:

Money {funds) coming from a partnership.

The Beast is very special.

CC won't sell, as she wants to take Precision all the way.

CC totally sincere. No b....hit.

CC at ESMO (has often has she attended exhibitions for Avacta?).

She has always convinced me that she believes in the platform & the benefits it could bring. Personally don't think she's in it for the money, more for the personal satisfaction of bringing (potentially) ground breaking science to those that need it.

Https://investors.tempus.com/news-releases/news-release-details/tempus-announces-acquisition-paige

I'm someone who knows something. But, is it the same something that someone wants to know?

Look over opti_mystic's 17.09 comments

BV. So, can wouldn't Tomlinson/Leeds have to provide/authorise a license to Coris? Can the original licence that was granted to Avacta be sold or transfered by Avacta. n they transfer those rights?

Thought Avacta owned the IP. Therefore, if Coris retain any interest in affimers it would only be under licence.

Saint. The link does include the 24 July purchase. Shows current short postion as 0.67%.

Good news if their algorithm continues to favour reducing/closing their position.

Their short can be read here

https://www.lse.co.uk/ShareShortPositions.html?shareprice=AVCT&share=Avacta-Group